DIABETES THERAPY TO IMPROVE BMI AND PULMONARY FUNCTION IN CYSTIC FIBROSIS

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。(1)接受胰岛素或瑞格列奈治疗的受试者与对照受试者相比，其BMI会增加。(2)在BMI增加时，胰岛素比瑞格列奈更有效。(3)BMI的增加主要是由于肌肉质量的增加。(4)BMI的增加将在膳食常量营养素或卡路里组成没有显著变化的情况下完成。(5)胰岛素或瑞格列奈治疗将防止肺功能下降相比，对照组和他们自己的基线测量前一年。这将与NIH临床评分的改善相关，并与体重增加和大腿肌肉体积增加直接相关。(6)接受胰岛素或瑞格列奈治疗的受试者将改善握力，这将与体重增加和大腿肌肉体积增加直接相关。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. (1) Participants receiving either insulin or repaglinide will increase their BMI compared to control participants. (2) Insulin will be more effective than repaglinide at increasing BMI. (3) The increase in BMI will be primarily due to increased muscle mass. (4) The increase in BMI will be accomplished without significant changes in dietary macronutrient or calorie composition. (5) Insulin or repaglinide therapy will prevent pulmonary function decline compared to both control subjects and to their own baseline as measured the previous year. This will be associated with improvement in NIH clinical score and will be directly related to weight gain and increase in thigh muscle volume. (6) Participants receiving insulin or repaglinide will improve hand grip strength, and this will be directly related to weight gain and increase in thigh muscle volume.